Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 8—August 2019
Dispatch

Case Series Study of Melioidosis, Colombia

José Y. RodríguezComments to Author , Soraya E. Morales-López, Gerson J. Rodríguez, Carlos A. Álvarez-Moreno, Kelin Esquea, Heidy Pinzon, Luis R. Ramirez, Lilian Moreno, Walter Ocampo, and Martha L. Cepeda
Author affiliations: Hospital Rosario Pumarejo de López, Valledupar, Colombia (J.Y. Rodríguez); Centro de Investigaciones Microbiológicas del Cesar (CIMCE), Valledupar (J.Y. Rodríguez, G.J. Rodríguez); Clínica Laura Daniela, Valledupar (J.Y. Rodríguez, K. Esquea); Clínica Médicos LTDA, Valledupar (J.Y. Rodríguez, H. Pinzon); Laboratorios Nancy Flórez García S.A.S., Valledupar (S.E. Moralez-López); Universidad Popular del Cesar, Valledupar (S.E. Moralez-López); Universidad Nacional de Colombia, Bogotá, Colombia (C.A. Álvarez-Moreno); Clínica Universitaria Colombia, Clínicas Colsanitas, Bogotá (C.A. Álvarez-Moreno); Grupo de Investigaciones Microbiológicas del Cesar, Valledupar (L.R. Ramirez, L. Moreno); Corporación CorpoGen, Bogotá (W. Ocampo, M.L. Cepeda)

Main Article

Table 2

Isolate dentification results by commercial systems, 16S rRNA sequencing analysis, and antimicrobial drug susceptibility of isolates of Burkholderia pseudomallei obtained from clinical specimens in the Caribbean coast region of Colombia*

Isolate no. Commercial bacterial identification systems
 ITS sequencing segments GenBank accession no.
Vitek (% probability) Walkaway/ Microscan (% probability) Phoenix
(% probability) MALDI-TOF MS (score) MIC, μg/mL
CAZ MER TMP/ SMX
1 ND B. pseudomallei (93%) ND ND ND ND 2 <1 <2/38
2 B. pseudomallei (99%) B. pseudomallei (99.5%) ND ND ND ND >16 <1 <2/38
3 B. pseudomallei (94%) B. pseudomallei (99.8%) ND ND ND ND 2 <1 <1/19
4 B. pseudomallei (94%) B. pseudomallei (99.9%) B. cepacia (99%) B. thailandensis (1,899) B. pseudomallei KX898558 4 1 2/38
5 B. pseudomallei (94%) B. pseudomallei (99.5%) B. cepacia (99%) B. thailandensis (1,898) B. pseudomallei KY659330 4 2 1/19
6 B. pseudomallei (95%) B. pseudomallei (99.9%) B. cepacia (99%) B. thailandensis (1,898) B. pseudomallei KY996759 4 1 1/19
7 B. pseudomallei (94%) B. pseudomallei (93%) B. cepacia (99%) B. thailandensis (1,898) B. pseudomallei KY659331 <2 2 1/19

*CAZ, ceftazidime; ITS, internal transcribed spacer; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; MER, meropenem; ND, no data; TMP/SMX, trimethoprim/sulfamethoxazole.

Main Article

Page created: July 16, 2019
Page updated: July 16, 2019
Page reviewed: July 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external